Patents for the current market-leading depression brands are due to expire in the major markets between 2012 and 2015, by which time competition in the market will be at its fiercest. In order to flourish in this harsh environment, new antidepressants must be sufficiently differentiated from conventional monoamine neurotransmitter reuptake inhibitors.

Features and benefits

Understand Datamonitor's independent appraisal of marketed brands and key pipeline agents indicated for treating depression.
Illustrate how pipeline and marketed drugs compare to one another in terms of clinical and commercial attributes.
Review important clinical developments for key pipeline agents with analysis of the latest clinical trial data.
Understand how marketed brands are positioned in the depression treatment algorithm and how they are perceived by psychiatrists.
Determine to what extent future therapies satisfy the main clinical unmet needs in depression treatment.

Highlights

Datamonitor's physician survey reveals that psychiatrists perceive Forest's and Lundbeck's selective serotonin reuptake inhibitor Lexapro (escitalopram) to be the leading depression treatment, with a superior efficacy and tolerability profile to other antidepressant brands.
TC-5214 (Targacept/AstraZeneca) and several pipeline antidepressants are poised to usurp Lexapro, following its loss of market exclusivity, and become the most attractive depression brands.
Forest's Viibryd (vilazodone) has the hallmarks of a new blockbuster - a novel mode of action, favorable tolerability, and the marketing prowess of Forest. Viibryd will be well received due to its good tolerability, although commercial success comparable to Lexapro will be unattainable as more innovative competitor drugs near the US market.

Your key questions answered

What is the gold-standard drug for depression?
How are marketed brands positioned in the depression treatment algorithm?
Which are the most likely drugs to emerge from the pipeline and how will they impact the way depression is treated?
What are the comparative strengths and weaknesses of the key depression brands and pipeline candidates?

CPI-300 (bupropion; IntelGenx)
AZD6765 (AstraZeneca)
BCI-224 (sabcomeline; BrainCells)
BCI-540 (coluracetam; BrainCells/Mitsubishi Tanabe)
BCI-952 (melatonin and buspirone; Brain Cells)
BMS-820836 (Bristol-Myers Squibb/AMRI)
Cariprazine (RGH-118; Forest/Gedeon Richter/Mitsubishi Tanabe)
Cimicoxib (UR-8880; Affectis Pharmaceuticals/Palau Pharma)
CP-601,927 (Pfizer)
EB-1010 (Euthymics Bioscience)
GLYX-13 (Naurex)
JNJ-26489112 (Johnson & Johnson)
Lu AA24530 (Lundbeck/Takeda)
OPC-34712 (Otsuka)
Orvepitant (GSK823296; GlaxoSmithKline)
PNB-01 (pipamperone and citalopram; PharmaNeuroBoost)
RG7090 (Roche)
SA4503 (cutamesine; M's Science)
Serdaxin (clavulanic acid; Rexah

簡介
目錄
相關商品

使用指南產品及服務須知網站導覽

星期一到星期五 / 9:30am - 6:00pm
TEL: 02-2729-4219 (+886-2-2729-4219)
E-mail: tw-info@gii.co.jp

憂鬱症:針對二線患者的新一代產品競爭

Product Profiles: Depression - Next generation vies for second-line patients

簡介

概要

摘要整理

市場定義和概要

上市產品簡介

產品線簡介

參考資訊

附錄

目錄

Description

Introduction

Features and benefits

Highlights

Your key questions answered

TOC

Executive Summary

OVERVIEW

MARKET DEFINITION AND OVERVIEW

MARKETED PRODUCT PROFILES

PIPELINE PRODUCT PROFILES

憂鬱症:針對二線患者的新一代產品競爭

Product Profiles: Depression - Next generation vies for second-line patients

簡介

概要

摘要整理

市場定義和概要

上市產品簡介

產品線簡介

參考資訊

附錄

目錄

Description

Introduction

Features and benefits

Highlights

Your key questions answered

TOC

Executive Summary

OVERVIEW

MARKET DEFINITION AND OVERVIEW

MARKETED PRODUCT PROFILES

PIPELINE PRODUCT PROFILES

相關商品

精神病相關市場調查報告書

Datamonitor發行的製藥相關市場調查報告書

Email Alert(Email 通知) - 最新市場調查報告書